
Jan van de Winkel and his team at Genmab will be more than a little busy in the time to come.
The company focuses on expanding its organization, which should take the firm from having only a single golden goose, cancer remedy Darzalex, to being an extensively branching and mature biotech venture.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app